Literature DB >> 29479838

Estimating the effect of a rare time-dependent treatment on the recurrent event rate.

Abigail R Smith1,2, Danting Zhu1, Nathan P Goodrich2, Robert M Merion2, Douglas E Schaubel1.   

Abstract

In many observational studies, the objective is to estimate the effect of treatment or state-change on the recurrent event rate. If treatment is assigned after the start of follow-up, traditional methods (eg, adjustment for baseline-only covariates or fully conditional adjustment for time-dependent covariates) may give biased results. We propose a two-stage modeling approach using the method of sequential stratification to accurately estimate the effect of a time-dependent treatment on the recurrent event rate. At the first stage, we estimate the pretreatment recurrent event trajectory using a proportional rates model censored at the time of treatment. Prognostic scores are estimated from the linear predictor of this model and used to match treated patients to as yet untreated controls based on prognostic score at the time of treatment for the index patient. The final model is stratified on matched sets and compares the posttreatment recurrent event rate to the recurrent event rate of the matched controls. We demonstrate through simulation that bias due to dependent censoring is negligible, provided the treatment frequency is low, and we investigate a threshold at which correction for dependent censoring is needed. The method is applied to liver transplant (LT), where we estimate the effect of development of post-LT End Stage Renal Disease (ESRD) on rate of days hospitalized.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  rate model; recurrent events; sequential stratification; time-dependent treatment; treatment effects

Mesh:

Year:  2018        PMID: 29479838      PMCID: PMC5943190          DOI: 10.1002/sim.7626

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Nonparametric analysis of recurrent events and death.

Authors:  D Ghosh; D Y Lin
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Shared frailty models for recurrent events and a terminal event.

Authors:  Lei Liu; Robert A Wolfe; Xuelin Huang
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

3.  Semiparametric analysis of correlated recurrent and terminal events.

Authors:  Yining Ye; John D Kalbfleisch; Douglas E Schaubel
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

4.  An estimating function approach to the analysis of recurrent and terminal events.

Authors:  John D Kalbfleisch; Douglas E Schaubel; Yining Ye; Qi Gong
Journal:  Biometrics       Date:  2013-05-07       Impact factor: 2.571

5.  Marginal analysis of recurrent events and a terminating event.

Authors:  R J Cook; J F Lawless
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

6.  Further results on the non-parametric linear regression model in survival analysis.

Authors:  O O Aalen
Journal:  Stat Med       Date:  1993-09-15       Impact factor: 2.373

7.  On the joint use of propensity and prognostic scores in estimation of the average treatment effect on the treated: a simulation study.

Authors:  Finbarr P Leacy; Elizabeth A Stuart
Journal:  Stat Med       Date:  2013-10-22       Impact factor: 2.373

8.  Estimating time-varying effects for overdispersed recurrent events data with treatment switching.

Authors:  Qingxia Chen; Donglin Zeng; Joseph G Ibrahim; Mouna Akacha; Heinz Schmidli
Journal:  Biometrika       Date:  2013       Impact factor: 2.445

9.  Matching methods for obtaining survival functions to estimate the effect of a time-dependent treatment.

Authors:  Yun Li; Douglas E Schaubel; Kevin He
Journal:  Stat Biosci       Date:  2014-05-01

10.  Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.

Authors:  Elizabeth A Stuart; Brian K Lee; Finbarr P Leacy
Journal:  J Clin Epidemiol       Date:  2013-08       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.